Front Desk: 469-391-0070
JAK Inhibitors: Uses, Benefits, and Side Effects Explained
Introduction: Key Points About Janus Kinase (JAK) Inhibitors
Janus kinase (JAK) inhibitors are a class of medications used to treat autoimmune and inflammatory conditions such as rheumatoid arthritis, psoriasis, and certain types of eczema. These medications work by targeting specific enzymes involved in the body’s immune response. By doing so, JAK inhibitors help reduce inflammation and prevent damage to joints and tissues. If you’re considering JAK inhibitors, consult one of our telemedicine providers to determine if this treatment is appropriate for you.
Medications within the Drug Class: Janus Kinase (JAK) Inhibitors
Cibinqo (abrocitinib)
Olumiant (baricitinib)
Rinvoq (upadacitinib)
The generic name of a medication refers to its chemical composition, while the brand name is the commercial name under which the drug is marketed. The generic name is listed in parentheses next to the brand name.
How Do JAK Inhibitors Work? Mechanism of Action Explained
JAK inhibitors block the activity of Janus kinases, enzymes that play a key role in the signaling pathways that regulate the immune system. Under normal circumstances, these enzymes help transmit signals from proteins called cytokines, which promote inflammation. By inhibiting JAK enzymes, these medications reduce the immune system’s inflammatory response, alleviating symptoms in conditions like rheumatoid arthritis and eczema.
While all JAK inhibitors target Janus kinases, different drugs in this class may block specific types of JAK enzymes (JAK1, JAK2, JAK3, or TYK2). For example, Cibinqo (abrocitinib) primarily inhibits JAK1, while Olumiant (baricitinib) inhibits both JAK1 and JAK2. Rinvoq (upadacitinib) also mainly targets JAK1. These differences can influence how the medications work and which conditions they are most effective in treating.
Benefits of Janus Kinase (JAK) Inhibitors
JAK inhibitors are often prescribed when other treatments, such as traditional disease-modifying antirheumatic drugs (DMARDs) or biologics, have not been effective. They offer a targeted approach to reducing inflammation and can be taken orally, unlike some treatments that require injections. JAK inhibitors are particularly beneficial for patients who have not responded well to other therapies, providing an alternative option for managing chronic autoimmune conditions.
Because JAK inhibitors work relatively quickly to reduce inflammation, they may offer faster symptom relief compared to some other treatments. However, it’s important to discuss the potential risks and benefits with your healthcare provider, as these medications can also have side effects. If you’re interested in learning more about JAK inhibitors, schedule a telemedicine appointment with one of our providers today.
Potential Side Effects of Janus Kinase (JAK) Inhibitors
Like all medications, Janus kinase (JAK) inhibitors can cause side effects. While not everyone will experience them, it’s important to be aware of potential issues and discuss any concerns with your healthcare provider. Some side effects are more common than others, and certain individuals may be at higher risk depending on their health status and other medications they are taking.
Common Side Effects (≥1%)
- Upper respiratory tract infections (13-16%): Symptoms may include a runny nose, sore throat, and cough. Patients with weakened immune systems may be at higher risk.
- Headache (7-10%): Some patients report mild to moderate headaches, which can usually be managed with over-the-counter pain relievers.
- Diarrhea (5-8%): Gastrointestinal discomfort, including diarrhea, is a common side effect. Staying hydrated and maintaining a balanced diet can help manage this symptom.
- Increased cholesterol levels (5-10%): JAK inhibitors can raise cholesterol levels, particularly LDL (“bad” cholesterol). Regular blood tests may be required to monitor this.
- Nausea (3-5%): Some patients may experience nausea, especially when starting the medication. Taking the medication with food may help reduce this symptom.
- Hypertension (2-4%): JAK inhibitors may cause an increase in blood pressure. Patients with a history of high blood pressure should monitor their levels closely.
Less Common Side Effects (<1%)
Some side effects occur less frequently but can still be serious. These include:
- Blood clots (deep vein thrombosis, pulmonary embolism)
- Serious infections (e.g., tuberculosis, herpes zoster)
- Elevated liver enzymes
- Gastrointestinal perforation
- Skin rash
- Fatigue
- Weight gain
- Allergic reactions
Severe Side Effects of JAK Inhibitors
Although rare, some side effects of JAK inhibitors can be severe. These include:
- Serious infections: JAK inhibitors can increase the risk of serious infections like tuberculosis, pneumonia, and shingles. Patients with a history of chronic infections or a weakened immune system should be especially cautious.
- Blood clots: There is a small but significant risk of developing blood clots, including deep vein thrombosis (DVT) and pulmonary embolism (PE). This risk may be higher in patients with a history of clotting disorders or those who are immobile for long periods.
- Cancer: Some studies suggest a potential increased risk of certain cancers, such as lymphoma and skin cancer, in patients taking JAK inhibitors. Regular skin checks and monitoring are recommended.
If you experience any of these severe side effects, contact your healthcare provider immediately. Before starting JAK inhibitors, it’s important to discuss your full medical history with your doctor, especially if you have a history of infections, blood clots, or cancer. Our telemedicine providers are available to help you assess your risks and determine if JAK inhibitors are the right choice for you.
Drug-to-Drug Interactions with JAK Inhibitors
JAK inhibitors can interact with other medications, potentially increasing side effects or reducing their effectiveness. It’s crucial to inform your healthcare provider about all the medications, supplements, and over-the-counter products you are taking. Some key interactions to be aware of include:
Biologic DMARDs (Disease-Modifying Anti-Rheumatic Drugs): Combining JAK inhibitors with biologic DMARDs, such as adalimumab or etanercept, significantly raises the risk of serious infections. These medications should not be used together.
Immunosuppressants: Medications like cyclosporine or azathioprine, which suppress the immune system, can further increase the risk of infections when taken alongside JAK inhibitors.
Blood thinners (anticoagulants): JAK inhibitors may increase the risk of blood clots. When combined with blood thinners like warfarin or aspirin, there is a potential for either increased bleeding or clotting, depending on the specific situation.
CYP3A4 inhibitors: Drugs that inhibit the CYP3A4 enzyme, such as ketoconazole or clarithromycin, can raise JAK inhibitor levels in the blood, heightening the risk of side effects.
Live vaccines: Live vaccines, such as the measles, mumps, and rubella (MMR) vaccine, should not be administered while taking JAK inhibitors due to the increased risk of infection.
Always consult your healthcare provider before starting or stopping any medications. Our telemedicine team is available to review your current medications and ensure there are no harmful interactions.
Precautions and Contraindications for JAK Inhibitors
Before starting JAK inhibitors, several important precautions and contraindications should be considered:
Infections: JAK inhibitors can increase the risk of infections. Patients with active infections, including chronic or recurrent infections, should not begin JAK inhibitors until the infection is fully resolved.
History of blood clots: Patients with a history of blood clots, such as deep vein thrombosis (DVT) or pulmonary embolism (PE), should use JAK inhibitors with caution, as these medications may elevate the risk of clotting.
Liver disease: JAK inhibitors can affect liver function. Patients with pre-existing liver conditions should be closely monitored through regular blood tests to ensure liver health.
Pregnancy and breastfeeding: The safety of JAK inhibitors during pregnancy and breastfeeding is not well established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the potential risks and benefits with their healthcare provider.
Age: Older adults may be more susceptible to side effects, particularly infections and blood clots. Dosing adjustments may be necessary for elderly patients to minimize these risks.
It’s essential to discuss your medical history and any potential risks with your healthcare provider before starting JAK inhibitors. If you have concerns, our telemedicine providers are available to guide you through the decision-making process and help determine if JAK inhibitors are the right choice for your condition.
Conclusion: Managing Your Health with JAK Inhibitors
Janus kinase (JAK) inhibitors offer an effective treatment option for autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. However, like all medications, they come with potential risks and side effects. Staying informed about these risks and maintaining open communication with your healthcare provider is key to managing your treatment safely.
If you are considering JAK inhibitors or have already been prescribed them, our telemedicine team is here to support you. We provide personalized advice, monitor your treatment, and ensure you are taking the right steps to manage your health effectively. Schedule a consultation with one of our providers today to discuss your treatment options and receive care from the comfort of your home.
